Last reviewed · How we verify
Intelence (ETRAVIRINE)
Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
Intelence (etravirine) is a small molecule non-nucleoside reverse transcriptase inhibitor developed by Janssen R And D. It targets the canalicular multispecific organic anion transporter 2 and is used to treat human immunodeficiency virus infection. Intelence was FDA approved in 2008 and is now available as a generic medication. As an off-patent medication, it is no longer protected by patents, allowing multiple generic manufacturers to produce it. Despite its off-patent status, Intelence remains a valuable treatment option for HIV patients.
At a glance
| Generic name | ETRAVIRINE |
|---|---|
| Sponsor | Janssen R And D |
| Drug class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] |
| Target | Canalicular multispecific organic anion transporter 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2008 |
Mechanism of action
Etravirine is an antiviral drug [see Microbiology (12.4) ].
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Rash
- Peripheral neuropathy
- Pancreatic amylase Grade 2
- Pancreatic amylase Grade 3
- Pancreatic amylase Grade 4
- Lipase Grade 2
- Lipase Grade 3
- Lipase Grade 4
- Creatinine Grade 2
- Creatinine Grade 3
- Decreased hemoglobin Grade 2
- Decreased hemoglobin Grade 3
Drug interactions
- fosamprenavir
- indinavir
- ketoconazole
- maraviroc
- nelfinavir
- nevirapine
- phenobarbital
- phenytoin
- rifabutin
- rifampicin
- rifapentine
- rilpivirine
Key clinical trials
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (PHASE1)
- Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination
- Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |